Skip to main content

Nizatidine (Monograph)

Brand name: Axid
Drug class: Histamine H2-Antagonists

Medically reviewed by Drugs.com on Oct 10, 2024. Written by ASHP.

Introduction

Histamine H2 receptor antagonist.1 2 3 4 5

Uses for Nizatidine

Gastroesophageal Reflux (GERD)

Short-term treatment of symptomatic GERD.1 2 39 40 41 42 43 44

Short-term treatment of esophagitis including erosion or ulcers (endoscopically diagnosed) in patients with GERD.1 2 39 40 41 42 43 44

Self-medication as initial therapy to achieve acid suppression, control symptoms, and prevent complications of less severe symptomatic GERD† [off-label].165

Short-term self-medication for relief of heartburn symptoms in adults and adolescents ≥12 years of age.b

Short-term self-medication for prevention of heartburn symptoms associated with acid indigestion and sour stomach brought on by ingestion of certain foods and beverages in adults and children ≥12 years of age.b

Duodenal Ulcer

Short-term treatment of active duodenal ulcer (endoscopically or radiographically confirmed).1 2 4 5 27 28 29 30 31 32 33 34

Maintenance of healing and reduction in recurrence of duodenal ulcer.1 2 4 5 16 35 36

Gastric Ulcer

Short-term treatment of active benign gastric ulcer.1 4 5 28 45 46 47

Nizatidine Dosage and Administration

Administration

Oral Administration

Administer orally1 2 3 4 5 without regard to meals.2 6 12

Antacids may be used as necessary for pain relief.2 5 27 28 29 30 31 32 33 34

Tablet for self-medication should be administered with a glass of water.b

For gastroesophageal reflux, once daily dosage not considered appropriate.165

For duodenal ulcer treatment, the advantage of administration once daily at bedtime (when convenience is important for compliance) over twice-daily administration has not been determined.2

For gastric ulcer treatment in adults, administer in divided doses twice daily or once daily at bedtime.1 45 46 47

Dosage

Pediatric Patients

Erosive Esophagitis or GERD
Oral

Children ≥12 years of age: 150 mg twice daily as oral solution for up to 8 weeks.c

Gastroesophageal Reflux
Self-medication for Heartburn in Adolescents ≥12 years of Age
Oral

75 mg once or twice daily (maximum 150 mg in 24 hours continuously for 2 weeks) or as directed by clinician.b

Self-medication for Prevention of Heartburn In Adolescents ≥12 Years of Age
Oral

75 mg once or twice daily (immediately or up to 1 hour before ingestion of causative food or beverage); maximum 150 mg in 24 hours continuously for 2 weeks or as directed by clinician.b

Adults

Gastroesophageal Reflux
Treatment of Esophagitis
Oral

150 mg twice daily for up to 12 weeks.1 2 40 41 42

300 mg at bedtime also has been used, but is less effective2 9 39 130 and not considered appropriate therapy.165

Self-medication for Heartburn
Oral

75 mg once or twice daily (maximum 150 mg in 24 hours continuously for 2 weeks) or as directed by clinician.b

Self-medication for Prevention of Heartburn
Oral

75 mg once or twice daily (immediately or up to 1 hour before ingestion of causative food or beverage); maximum 150 mg in 24 hours continuously for 2 weeks or as directed by clinician.b

Duodenal Ulcer
Treatment of Active Duodenal Ulcer
Oral

300 mg once daily at bedtime, or 150 mg twice daily.1 2

Healing may occur within 2 weeks in some, and within 4 weeks in most patients;1 2 27 28 29 30 31 32 33 34 some patients may benefit from an additional 4 weeks of therapy.1 2 Occasionally may be necessary to continue full-dose therapy for >6–8 weeks.1 2

Safety and efficacy of continuing full-dose therapy for > 8 weeks have not been established.1 2

Maintenance of Healing of Duodenal Ulcer
Oral

150 mg once daily at bedtime.1 2 35 36

Some clinicians recommend continuing maintenance therapy for at least 1 year.4

Safety and efficacy of continuing maintenance therapy beyond 1 year have not been established.1

Gastric Ulcer
Oral

150 mg twice daily or 300 mg once daily at bedtime for up to 8 weeks.1 45 46 47

Complete healing of gastric ulcers usually occurs within 8 weeks.1 4 5 28 45 46 47

Safety and efficacy for >8 weeks have not been established.1 126

Prescribing Limits

Pediatric Patients

Erosive Esophagitis or GERD
Oral

Maximum 300 mg daily for 8 weeks.c

Gastroesophageal Reflux
Self-Medication For Heartburn in Adolescents ≥12 years of Age
Oral

Maximum 150 mg in 24 hours continuously for 2 weeks.b

Self-medication for Prevention of Heartburn in Adolescents ≥12 years of Age
Oral

Maximum 150 mg in 24 hours continuously for 2 weeks.b

Adults

Gastroesophageal Reflux
Treatment of Esophagitis
Oral

Safety and efficacy for >12 weeks not established.1 2 40 41 42

Self-medication for Heartburn
Oral

Maximum 150 mg in 24 hours continuously for 2 weeks.b

Self-medication for Prevention of Heartburn
Oral

Maximum 150 mg in 24 hours continuously for 2 weeks.b

Duodenal Ulcer
Treatment of Active Duodenal Ulcer
Oral

Safety and efficacy for >8 weeks not established.1 2

Maintenance of Healing of Duodenal Ulcer
Oral

Safety and efficacy for >1 year not established.1

Gastric Ulcer
Short-term treatment of Active Benign Gastric Ulcer
Oral

Safety and efficacy for >8 weeks not established.1 126

Special Populations

Renal Impairment

Modify doses and/or frequency of administration to the degree of renal impairment; clinical efficacy of recommended dosages have not been systematically evaluated.1 2 22

Table 1. Nizatidine Dosage Based on Creatinine Clearance

Creatinine Clearance (mL/minute)

Dosage for Treatment of Esophagitis, Active Duodenal Ulcer, Active Benign Gastric Ulcer1 2 22

Dosage for Maintenance of Healing of Duodenal Ulcer1 2

20–50

150 mg once daily

150 mg once every other day

<20

150 mg once every other day

150 mg once every 3 days

Geriatric Patients

Careful dosage selection recommended due to possible age-related decreases in renal function.1 2 Monitoring renal function may be useful.a

Detailed Nizatidine dosage information

Cautions for Nizatidine

Contraindications

Warnings/Precautions

General Precautions

Gastric Malignancy

Response to nizatidine does not preclude presence of gastric malignancy.1

Respiratory Effects

Administration of H2-receptor antagonists has been associated with an increased risk for developing certain infections (e.g., community-acquired pneumonia).175

Specific Populations

Pregnancy

Category B.1 10

Self-medication in pregnant women: consult a clinician before using.1

Lactation

Distributed into milk.1 21 Discontinue nursing or the drug.1

Self-medication in nursing women: consult a clinician before using.b

Pediatric Use

Efficacy not established in children <12 years of age.1 126

Safety and efficacy for self-medication not established in children <12 years of age; do not use unless directed by a clinician.b

Geriatric Use

No substantial differences in safety and efficacy in those ≥65 years of age relative to younger adults, and dosage adjustment solely on the basis of age generally is not required.1 2 5

Possibility exists of greater sensitivity in some geriatric individuals.a

Substantially eliminated by the kidneys; because geriatric patients are more likely to have decreased renal function, use caution in dosage selection.a Monitoring of renal function may be useful.a In geriatric patients with renal impairment, modify dose and frequency of administration in response to the degree of renal impairment.1 2 (See Renal Impairment under Dosage and Administration).

Renal Impairment

Use with caution.1 Dosage adjustments necessary based on degree of renal impairment.1 (See Renal Impairment under Dosage and Administration).

Common Adverse Effects

Headache, dizziness.1 2 5 31 33 34 40 41 46 50

Drug Interactions

Does not inhibit hepatic metabolism of drugs by hepatic CYP isoenzymes.1 14

Specific Drugs and Laboratory Tests

Drug/Food/Lab Test

Interaction

Comment

Alcohol

Potential for changes in blood alcohol concentrations, but conflicting data74 75 76 78 79 80 81 82 83 126 129

Potential for psychomotor impairment controversial,74 75 76 77 78 79 80 but use caution during performance of hazardous tasks requiring mental alertness, physical coordination75 76 79 80 126

Antacids

Slight but clinically unimportant decrease in nizatidine bioavailability1 2 4 5 6 9 12

Used concomitantly as necessary for pain relief2 5 27 28 29 30 31 32 33 34

Multistix test for urobilinogen1

False positive1

Salicylate (high-dose aspirin)

Possible inhibition of salicylate excretion and increased serum salicylate concentrations1 2 5 124
Nizatidine drug interactions (more detail)

Nizatidine Pharmacokinetics

Absorption

Bioavailability

About 70%.1 2 9 12 16

Onset

Gastric acid inhibition within 30 minutes after IV administration.6 19

Duration

Dose dependent.2 6 19

Nocturnal gastric acid secretion is inhibited for 10–12 hours after a single 300-mg dose.1 2 4 7 8

Inhibition of food-stimulated secretion generally persists for up to 4 hours following a 150- or 300-mg dose.1 2 20

Food

May slightly enhance bioavailability.1 2 4 5 6 9 12

Distribution

Extent

Not fully characterized.4

Nizatidine crosses the placenta5 26 and is distributed into milk.1 21

Plasma Protein Binding

35%, mainly to α1-acid glycoprotein.1 2 3 5 6 15

Elimination

Metabolism

Metabolized in the liver to active N-desmethylnizatidine (60% as active as nizatidine in blocking acid secretion), and inactive nizatidine N-oxide and nizatidine sulfoxide.1 2 5 15 22

Minimal first pass metabolism.1 2

Elimination Route

Excreted principally in urine1 2 3 15 (90%);1 5 6 15 about 60–65% is excreted unchanged,1 2 5 6 22 8% is excreted as N-desmethylnizatidine, 6% as nizatidine sulfoxide, 6% as nizatidine N-oxide, and about 15% as unidentified metabolites.1 2 5 6 15 <6% of a dose is eliminated in feces.1 2 5 6 15

Half-life

1–2 hours.1 2 3 4 5 6 9 12 16 22 23

Special Populations

In patients with renal impairment, half-life averages 2.1 hours when Clcr is 50–75 mL/minute, 4.1 hours when Clcr is 10–49 mL/minute, and ranges from 3.5–11 hours in anuric patients.1 2 3 5 6 22 23

Does not appear to be removed appreciably by hemodialysis.1 22 23

Stability

Storage

Oral

Capsules

Tight, light-resistant containers at 20–25°C (may be exposed to 15–30°C).a

Tablets for Self-medication

Tight, light-resistant containers at 20–25°C.b

Actions

Advice to Patients

Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Nizatidine

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

150 mg

Axid Pulvules

Reliant

300 mg

Axid Pulvules (with povidone)

Reliant

Solution

15 mg/mL

Axid

Reliant

Tablets

75 mg

Axid AR Acid Reducer

Wyeth

AHFS DI Essentials™. © Copyright 2025, Selected Revisions October 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Eli Lilly and Company. Axid Pulvules (nizatidine) capsules prescribing information. Indianapolis, IN; 1994 Sep.

2. Eli Lilly and Company. Axid (nizatidine) product information. Indianapolis, IN; 1992. Publication No. 60-NZ-0390-1.

3. Feldman M, Burton ME. Histamine2-receptor antagonists: standard therapy for acid-peptic diseases. N Engl J Med. 1990; 323:1672-80. https://pubmed.ncbi.nlm.nih.gov/1978250

4. Anon. Nizatidine (Axid). Med Lett Drugs Ther. 1988; 30:77-8. https://pubmed.ncbi.nlm.nih.gov/2899835

5. Price AH, Brogden RN. Nizatidine: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs. 1988; 36:521-39. https://pubmed.ncbi.nlm.nih.gov/2905640

6. Callaghan JT, Bergstrom RF, Rubin A et al. A pharmacokinetic profile of nizatidine in man. Scand J Gastroenterol. 1987; 22(Suppl 136):9-17.

7. Kovacs TOG, Van Deventer GM, Maxwell V et al. The effect of an oral evening dose of nizatidine on nocturnal and peptone-stimulated gastric acid and gastrin secretion. Scand J Gastroenterol. 1987; 22(Suppl 136):41-6.

8. Dammann HG, Gottlieb WR, Walter TA et al. The 24-hour acid suppression profile of nizatidine. Scand J Gastroenterol. 1987; 22(Suppl 136):56-60.

9. Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Clin Pharmacokinet. 1991; 20: 218-36. https://pubmed.ncbi.nlm.nih.gov/1673880

10. Morton DM. Pharmacology and toxicology of nizatidine. Scand J Gastroenterol. 1987; 22(Suppl 136):1-8. https://pubmed.ncbi.nlm.nih.gov/3551046

11. Klotz U. Lack of effect of nizatidine on drug metabolism. Scand J Gastroenterol. 1987; 22(Suppl 136):18-23.

12. Knadler MP, Bergstrom RF, Callaghan JT et al. Absorption studies of the H2-blocker nizatidine. Clin Pharmacol Ther. 1987; 42: 514-20. https://pubmed.ncbi.nlm.nih.gov/2890459

13. Bachmann K, Sullivan TJ, Mauro LS et al. Comparative investigation of the influence of nizatidine, ranitidine, and cimetidine on the steady-state pharmacokinetics of theophylline in COPD patients. J Clin Pharmacol. 1992; 32:476-82. https://pubmed.ncbi.nlm.nih.gov/1587967

14. Hussey EK, Dukes GE. Do all histamine2-antagonists cause a warfarin drug interaction? Drug Intell Clin Pharm. 1989; 23:675-9.

15. Knadler MP, Bergstrom RF, Callaghan JT et al. Nizatidine, an H2-blocker: its metabolism and disposition in man. Drug Metabol Dispos. 1986; 14:175-82.

16. Shamburek RD, Schubert ML. Pharmacology of gastric acid inhibition. Bailliére’s Clin Gastroenterol. 1993; 7:23-54.

17. Schneck DW, Callaghan JT, Bergstrom RF et al. Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion. Clin Pharmacol Ther. 1990; 47:499-503. https://pubmed.ncbi.nlm.nih.gov/2109665

18. Cournot A, Berlin I, Sallord JC et al. Lack of interaction between nizatidine and warfarin during chronic administration. J Clin Pharmacol. 1988; 28:1120-2. https://pubmed.ncbi.nlm.nih.gov/2907521

19. Callaghan JT, Bergstrom RF, Obermeyer BD et al. Intravenous nizatidine kinetics and acid suppression. Clin Pharmacol Ther. 1985; 37:162-5. https://pubmed.ncbi.nlm.nih.gov/2857117

20. Vargas R, Ryan J, McMahon G et al. Pharmacokinetics and pharmacodynamics of oral nizatidine. J Clin Pharmacol. 1988; 28:71-5. https://pubmed.ncbi.nlm.nih.gov/2895125

21. Obermeyer BD, Bergstrom RF, Callaghan JT et al. Secretion of nizatidine into human breast milk after single and multiple doses. Clin Pharmacol Ther. 1990; 47:724-30. https://pubmed.ncbi.nlm.nih.gov/1972674

22. Aronoff GR, Bergstrom RF, Bopp RJ et al. Nizatidine disposition in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1988; 43:688-95. https://pubmed.ncbi.nlm.nih.gov/2897890

23. Gladziwa U, Klotz U. Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency. Clin Pharmacokinet. 1993; 24:319-32. https://pubmed.ncbi.nlm.nih.gov/8098275

24. Villani P, Regazzi MB, Pecorini M et al. The effect of aging on the pharmacokinetics of nizatidine. Eur J Drug Metab Pharmacokinet. 1991; 3:205-10.

25. Callaghan JT, Rubin A, Knadler MP et al. Nizatidine, an H2-receptor antagonist: disposition and safety in the elderly. J Clin Pharmacol. 1987; 27:618-24. https://pubmed.ncbi.nlm.nih.gov/2888796

26. Schenker S, Johnson R, Mor L et al. Human placental transport of cimetidine (C), ranitidine (R) and nizatidine (N). Clin Res. 1986; 34:445A.

27. Simon B, Cremer M, Dammann HG et al. 300 Mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer. Scand J Gastroenterol. 1987; 22(Suppl 136):61-70.

28. Kuipers EJ, Hazenberg HJA, Quik RFP et al. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial. Neth J Med. 1990; 37:58-62. https://pubmed.ncbi.nlm.nih.gov/1977089

29. Cloud ML, Offen WW, Matsumoto C et al. Healing and recurrence of active duodenal ulcer with nizatidine. Clin Pharmacol Ther. 1989; 46:310-6. https://pubmed.ncbi.nlm.nih.gov/2570656

30. Cherner JA, Cloud ML, Offen WW et al. Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Am J Gastroenterol. 1989; 84:769-74. https://pubmed.ncbi.nlm.nih.gov/2568086

31. Pace F, Colombo E, Ferrara A et al. Nizatidine and ranitidine in the short-term treatment of duodenal ulcer: a cooperative double-blind study of once-daily bedtime administration. Am J Gastroenterol. 1988; 83: 643-5. https://pubmed.ncbi.nlm.nih.gov/2897784

32. Levendoglu H, Mehta B, Wait C et al. Nizatidine: a new histamine receptor blocker in the treatment of active duodenal ulcers. Am J Gastroenterol. 1986; 81:1167-70. https://pubmed.ncbi.nlm.nih.gov/2878607

33. Cloud ML, Offen WW, Matsumoto C et al. Healing and subsequent recurrence of duodenal ulcer in a clinical trial comparing nizatidine 300-mg and 100-mg evening doses and placebo in the treatment of active duodenal ulcer. Curr Ther Res. 1989; 45:359-67.

34. Bovero E, Poletti M, Boero A et al. Nizatidine in the short-term treatment off duodenal ulcer—an Italian multicenter study. Hepatogastroenterology. 1987; 34:269-72. https://pubmed.ncbi.nlm.nih.gov/2892768

35. Cerulli MA, Cloud ML, Offen WW et al. Nizatidine as maintenance therapy of duodenal ulcer disease in remission. Scand J Gastroenterol. 1987; 22(Suppl 136):79-83.

36. Hentschel E, Schütze K, Reichel W et al. Nizatidine versus ranitidine in the prevention of duodenal ulcer relapse: six-month interim results of a European multicentre study. Scand J Gastroenterol. 1987; 22(Suppl 136):84-8.

37. Desager JP, Harvengt C. Oral bioavailability of nizatidine and ranitidine concurrently administered with antacid. J Int Med Res. 1989; 17:62-7. https://pubmed.ncbi.nlm.nih.gov/2565267

38. Probst KS, Higdon GL, Fisher LF et al. Preclinical toxicology studies with nizatidine, a new H2-receptor antagonist: acute, subchronic, and chronic toxicity evaluations. Fundament Appl Toxicol. 1989; 13: 778-92.

39. Sontag SJ. The medical management of reflux esophagitis: role of antacids and acid inhibition. Gastroenterol Clin N Amer. 1990; 19: 683-712.

40. Cloud ML, Offen WW, Nizatidine Gastroesophageal Reflux Disease Study Group. Nizatidine versus placebo in gastroesophageal reflux disease: a six-week, multicenter, randomized, double-blind comparison. Dig Dis Sci. 1992; 37:865-74. https://pubmed.ncbi.nlm.nih.gov/1587191

41. Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol. 1991; 86:1735-42. https://pubmed.ncbi.nlm.nih.gov/1962618

42. Quik RFP, Cooper MJ, Gleeson M et al. A comparison of two doses of nizatidine versus placebo in the treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1990; 4:201-11. https://pubmed.ncbi.nlm.nih.gov/1983322

43. Hixson LJ, Kelley CL, Jones WN et al. Current trends in the pharmacotherapy for gastroesophageal reflux disease. Arch Intern Med. 1992; 152:717-23. https://pubmed.ncbi.nlm.nih.gov/1558428

44. Garnett WR. Efficacy, safety, and cost issues in managing patients with gastroesophageal reflux disease. Am J Hosp Pharm. 1993; 50:S11-8. https://pubmed.ncbi.nlm.nih.gov/8097363

45. Naccaratto R, Cremer M, Dammann HG et al. Nizatidine versus ranitidine in gastric ulcer disease. Scand J Gastroenterol. 1987; 22(Suppl 136):71-8.

46. Cloud ML, Enas N, Offen WW et al. Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison. Clin Pharmacol Ther. 1992; 52:307-13. https://pubmed.ncbi.nlm.nih.gov/1526089

47. Di Mario F, Battaglia G, Naccarato R et al. Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer—an 8-week randomized, double-blind multicentre study. Hepatogastroenterology. 1990; 37(Suppl II):62-5. https://pubmed.ncbi.nlm.nih.gov/1982108

48. Secor JW, Speeg KV Jr, Meredith CG et al. Lack of effect of nizatidine on hepatic drug metabolism in man. Br J Clin Pharmacol. 1985; 20: 710-3. https://pubmed.ncbi.nlm.nih.gov/2868746

49. Van Thiel DH, Gavaler JS, Heyl A et al. An evaluation of the anti-androgen effects associated with H2 antagonist therapy. Scand J Gastroenterol. 1987; 22(Suppl 136):24-8. https://pubmed.ncbi.nlm.nih.gov/3563408

50. Cloud ML. Safety of nizatidine in clinical trials conducted in the USA and Europe. Scand J Gastroenterol. 1987; 22(Suppl 136):29-36. https://pubmed.ncbi.nlm.nih.gov/3563409

51. Aymard JP, Aymard B, Netter P et al. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp. 1988; 3: 430-48. https://pubmed.ncbi.nlm.nih.gov/2905759

52. Cantü TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Int Med. 1991; 114:1027-34. https://pubmed.ncbi.nlm.nih.gov/1674198

53. Kassianos GC. Impotence and nizatidine. Lancet. 1989; 1:963. https://pubmed.ncbi.nlm.nih.gov/2565456

54. Lin TM, Evans DC, Warrick MW et al. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs. J Pharmacol Exp Ther. 1986; 239:406-10. https://pubmed.ncbi.nlm.nih.gov/2877081

55. Lin TM, Evans DC, Warrick MW et al. Actions of nizatidine on the rat uterus, dog stomach and experimentally induced gastric lesions. J Pharmacol Exp Ther. 1986; 239:400-5. https://pubmed.ncbi.nlm.nih.gov/3095539

56. Dammann HG, Gottlieb WR, Walter TA et al. Nocturnal acid suppression with a new H2 receptor antagonist—nizatidine. Hepatogastroenterology. 1986; 33:217-20. https://pubmed.ncbi.nlm.nih.gov/2879782

57. Danziger L, Furmaga KM, Rodvold KA et al. Nizatidine suppression of basal gastric acid output: a comparison of two intravenous dosage regimens. J Clin Pharmacol. 1989; 29:946-52. https://pubmed.ncbi.nlm.nih.gov/2574190

58. Savarino V, Mela GS, Zentilin P et al. Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg. J Clin Pharmacol. 1993; 33:70-4. https://pubmed.ncbi.nlm.nih.gov/8429117

59. Bemis K, Bendele A, Clemens J et al. General pharmacology of nizatidine in animals. Arzneimittelforschung. 1989; 39:240-50. https://pubmed.ncbi.nlm.nih.gov/2567169

60. Halabi A, Kirch W. Negative chronotropic effects of nizatidine. Gut. 1991; 32:630-4. https://pubmed.ncbi.nlm.nih.gov/1676392

61. Hinrichsen H, Halabi A, Kirch W. Hemodynamic effects of different H2-receptor antagonists. Clin Pharamcol Ther. 1990; 48: 302-8.

62. Kirch W, Halari H, Ohnhaus EE. Negative inotropic effects of famotidine. Lancet. 1987; 2:684-5. https://pubmed.ncbi.nlm.nih.gov/2887963

63. Tanner LA, Arrowsmith JB. Bradycardia and H2 antagonists. Ann Intern Med. 1988; 109:434-5. https://pubmed.ncbi.nlm.nih.gov/3408059

64. Hinrichsen H, Halabi A, Fuhrmann G et al. Dose-dependent heart rate reducing effect of nizatidine, a histamine H2-receptor antagonist. Br J Clin Pharmacol. 1993; 35:461-6. https://pubmed.ncbi.nlm.nih.gov/8099802

65. Laine-Cessac P, Turcant A, Premel-Cabic A et al. Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res Comm Chem Pathol Pharmacol. 1993; 79:185-93.

66. Bonfils S. Nizatidine versus ranitidine: evolution of drug antisecretory efficacy over a 28-day period. Curr Ther Res. 1992; 52:859-62.

67. Fullarton GM, McLauchlan G, MacDonald A et al. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist. Gut. 1989; 30:449-54. https://pubmed.ncbi.nlm.nih.gov/2565860

68. Fullarton GM, MacDonald AMI, McColl KEL. Rebound hypersecretion after H2-antagonist withdrawal—a comparative study with nizatidine, ranitidine and famotidine. Aliment Pharmacol Ther. 1991; 5:391-8. https://pubmed.ncbi.nlm.nih.gov/1685675

69. Nwokolo CU, Smith JTL, Sawyerr AM et al. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade. Gut. 1991; 32:1455-60. https://pubmed.ncbi.nlm.nih.gov/1685465

70. Lazzaroni M, Sangaletti O, Porro GB. The effect of a single oral morning dose of nizatidine and ranitidine on intragastric pH under basal conditions and after pentagastrin stimulation. J Int Med Res. 1992; 20:454-60. https://pubmed.ncbi.nlm.nih.gov/1286739

71. Savarino V, Mela GS, Zentilin P et al. Lack of gastric acid rebound after stopping a successful short-term course of nizatidine in duodenal ulcer patients. Am J Gastroenterol. 1991; 86:281-4. https://pubmed.ncbi.nlm.nih.gov/1671805

72. Cryer B, Feldman M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal anti-inflammatory drug-induced damage. Arch Intern Med. 1992; 152:1145-55. https://pubmed.ncbi.nlm.nih.gov/1599341

73. Klotz U, Gottlieb W, Keohane PP et al. Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. J Clin Pharmacol. 1987; 27:210-2. https://pubmed.ncbi.nlm.nih.gov/2890666

74. Raufman JP, Notar-Francesco V, Raffaniello RD et al. Histamine-2 receptor antagonists do not alter serum ethanol levels in fed, nonalcoholic men. Ann Intern Med. 1993; 118:488-94. https://pubmed.ncbi.nlm.nih.gov/8095127

75. Lewis JH, McIsaac RL. H2 antagonists and blood alcohol levels. Dig Dis Sci. 1993; 38:569-71. https://pubmed.ncbi.nlm.nih.gov/8095199

76. Roine R, Hernández-Munoz R, Baraona E et al. H2 antagonists and blood alcohol levels. Dig Dis Sci. 1993; 38:572-3.

77. Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1993; 153:2449-54. https://pubmed.ncbi.nlm.nih.gov/8215749

78. Anon. H2 blocker interaction with alcohol is not clinically significant, FDA advisory committee concludes March 12; issue may be revisited, agency indicates. FDC Rep Drugs Cosmet. 1993 Mar 22:10.

79. Levitt MD. Do histamine-2 receptor antagonists influence the metabolism of ethanol? Ann Intern Med. 1993; 118:564-5. Editorial.

80. Marshall JM. Interaction of histamine2-receptor antagonists and ethanol. Ann Pharmacother. 1994; 28:55-6. https://pubmed.ncbi.nlm.nih.gov/7907240

81. Fraser AG, Prewett EJ, Hudson M et al. The effect of ranitidine, cimetidine or famotidine on low-dose post-prandial alcohol absorption. Aliment Pharmacol Ther. 1991; 5:263-72. https://pubmed.ncbi.nlm.nih.gov/1888825

82. Fraser AG, Hudson M, Sawyer AM et al. Short report: the effect of ranitidine on the post-prandial absorption of a low dose of alcohol. Aliment Pharmacol Ther. 1992; 6:267-71. https://pubmed.ncbi.nlm.nih.gov/1600045

83. Palmer RH, Frank WO, Nambi P et al. Effects of various concomitant medications on gastric alcohol dehydrogenase and the first-pass metabolism of ethanol. Am J Gastroenterol. 1991; 86:1749-55. https://pubmed.ncbi.nlm.nih.gov/1683743

84. Ateshkadi A, Lam NP, Johnson CA. Helicobacter pylori and peptic ulcer disease. Clin Pharm. 1993; 12:34-48. https://pubmed.ncbi.nlm.nih.gov/8428432

85. Blaser MJ. Helicobacter pylori: its role in disease. Clin Infect Dis. 1992; 15:386-91. https://pubmed.ncbi.nlm.nih.gov/1520782

86. Murray DM, DuPont HL, Cooperstock M et al. Evaluation of new anti-infective drugs for the treatment of gastritis and peptic ulcer disease associated with infection by Helicobacter pylori . Clin Infect Dis. 1992; 15(Suppl 1):S268-73.

87. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991; 324:1043-8. https://pubmed.ncbi.nlm.nih.gov/2005942

88. Graham DY, Go MF. Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated. Clin Infect Dis. 1993; 17:293-4. https://pubmed.ncbi.nlm.nih.gov/8399892

89. Labenz J, Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut. 1994; 35:19-22. https://pubmed.ncbi.nlm.nih.gov/8307443

90. Levine TS, Price AB. Helicobacter pylori: enough to give anyone an ulcer! Br J Clin Pract. 1994; 47:328-32.

91. Forbes GM, Glaser ME, Cullen DJ et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet. 1994; 343:258-60. https://pubmed.ncbi.nlm.nih.gov/7905095

92. Fiocca R, Solcia E, Santoro B. Duodenal ulcer relapse after eradication of Helicobacter pylori . Lancet. 1991; 337:1614. https://pubmed.ncbi.nlm.nih.gov/1675746

93. Marshall BJ. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Clin Infect Dis. 1990; 12(Suppl 1):S87-93.

94. Marshall BJ. Treatment strategies for Helicobacter pylori infection. Gastroenterol Clin North Am. 1993; 22:183-98. https://pubmed.ncbi.nlm.nih.gov/8449566

95. Glassman MS. Helicobacter pylori infection in children. A clinical overview. Clin Pediatr (Phila). 1992; 31:481-7. https://pubmed.ncbi.nlm.nih.gov/1643767

96. Bianchi Porro G, Parente F, Lazzaroni M. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Gut. 1993; 34:466-9. https://pubmed.ncbi.nlm.nih.gov/8491391

97. Borody T, Andrews P, Mancuso N et al. Helicobacter pylori reinfection 4 years post-eradication. Lancet. 1992; 339:1295. https://pubmed.ncbi.nlm.nih.gov/1349686

98. Hixson LJ, Kelley CL, Jones WN et al. Current trends in the pharmacotherapy for peptic ulcer disease. Arch Intern Med. 1992; 152:726-32. https://pubmed.ncbi.nlm.nih.gov/1558429

99. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer with eradication of Helicobacter pylori . Lancet. 1990; 335:1233-5. https://pubmed.ncbi.nlm.nih.gov/1971318

100. NIH Consensus Development Panel on. Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994; 272:65-9. https://pubmed.ncbi.nlm.nih.gov/8007082

101. Cotton P. NIH consensus panel urges antimicrobials for ulcer patients, skeptics concur with caveats. JAMA. 1994; 271:808-9. https://pubmed.ncbi.nlm.nih.gov/8114221

102. Feldman M. The acid test. Making clinical sense of the consensus conference on Helicobacter pylori . JAMA. 1994; 272:70-1. https://pubmed.ncbi.nlm.nih.gov/8007084

103. Graham DY, Lew GM, Evans DG et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med. 1991; 115:266-9. https://pubmed.ncbi.nlm.nih.gov/1854110

104. Reviewers’ comments (personal observations) on the Aminopenicillins General Statement (Uses: Helicobacter pylori infections).

105. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol. 1994; 29 Suppl 201:16-23.

106. Fennerty MB. Helicobacter pylori. Ann Intern Med. 1994; 154:721-7.

107. Chiba N, Rao BV, Rademaker JW et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori . Am J Gastroenterol. 1992; 87:1716-27. https://pubmed.ncbi.nlm.nih.gov/1449132

108. Hentschel E, Brandstatter G, Dragosics B et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993; 328:308-12. https://pubmed.ncbi.nlm.nih.gov/8419816

109. Sloane R, Cohen H. Common-sense management of Helicobacter pylori-associated gastroduodenal disease. Personal views. Gastroenterol Clin North Am. 1993; 22:199-206. https://pubmed.ncbi.nlm.nih.gov/8449567

110. Katelaris P. Eradicating Helicobacter pylori . Lancet. 1992; 339:54. https://pubmed.ncbi.nlm.nih.gov/1345965

111. Burette A, Glupczynski Y. On: The who’s and when’s of therapy for Helicobacter pylori . Am J Gastroenterol. 1991; 86:924-5. https://pubmed.ncbi.nlm.nih.gov/2058644

112. Bell GD, Powell K, Burridge SM et al. Experience with ″triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther. 1992; 6:427-35. https://pubmed.ncbi.nlm.nih.gov/1420735

113. Bayerdorffer E, Mannes GA, Sommer A et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol Suppl. 1993; 196:19-25. https://pubmed.ncbi.nlm.nih.gov/8341987

114. Unge P, Ekstrom P. Effects of combination therapy with omeprazole and an antibiotic on H. pylori and duodenal ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:17-8.

115. Hunt RH. Hp and pH: implications for the eradication of Helicobacter pylori . Scand J Gastroenterol Suppl. 1993; 196:12-6. https://pubmed.ncbi.nlm.nih.gov/8341986

116. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl. 1993; 196:34-7. https://pubmed.ncbi.nlm.nih.gov/8341989

117. Bell GD, Powell U. Eradication of Helicobacter pylori and its effect in peptic ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:7-11. https://pubmed.ncbi.nlm.nih.gov/8341990

118. Hunt RH. pH and Hp—gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993; 88:481-3. https://pubmed.ncbi.nlm.nih.gov/8470623

119. Labenz J, Ruhl GH, Bertrams J et al. Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol. 1994; 89:726-30. https://pubmed.ncbi.nlm.nih.gov/8172146

120. Adamek RJ, Wegener M, Labenz J et al. Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol. 1994; 89:39-42. https://pubmed.ncbi.nlm.nih.gov/8273795

121. Fennerty MB. Helicobacter pylori. Arch Intern Med. 1994; 154:721-7. https://pubmed.ncbi.nlm.nih.gov/8147675

122. Bossa R, Baggio G, Caffero L et al. The effect of nizatidine on neuromuscular transmission. In Vivo. 1992; 6:597-600. https://pubmed.ncbi.nlm.nih.gov/1338367

123. Berlin RG, Clineschmidt BV, Majka JA. Famotidine: an appraisal of its mode of action and safety. Am J Med. 1986; 81(Suppl 4B):8-12. https://pubmed.ncbi.nlm.nih.gov/2877577

124. Callaghan JT, Ridolfo AS, Crabtree RE et al. Nizatidine: effect on aspirin-induced gastrointestinal red blood cell loss. Pharmacologist. 1987; 29:216: Abstract.

125. The United States pharmacopeia, 23nd rev, and The national formulary, 18th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1995:11.

126. Lilly, Indianapolis, IN: Personal communication.

127. Reviewers’ comments (personal observations).

128. Peura DA, Graham DY. Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol. 1994; 89:1137-9. https://pubmed.ncbi.nlm.nih.gov/8053422

129. Gugler R. H2-antagonists and alcohol: do they interact? Drug Safety. 1994; 10:271-80.

130. Rex DK. Gastroesophageal reflux disease in adults: pathophysiology, diagnosis, and management. J Fam Pract. 1992; 35:673-81. https://pubmed.ncbi.nlm.nih.gov/1453152

131. Farrell MK. Dr. Apley meets Helicobacter pylori. J Pediatr Gastroenterol Nutr. 1993; 16:118-9. https://pubmed.ncbi.nlm.nih.gov/8450375

132. Nomura A, Stemmermann GN, Chyou PH et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325:1132-6. https://pubmed.ncbi.nlm.nih.gov/1891021

133. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127-31. https://pubmed.ncbi.nlm.nih.gov/1891020

134. The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993; 341:1359-62. https://pubmed.ncbi.nlm.nih.gov/8098787

135. Talley NJ, Zinsmeister AR, Weaver A et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst. 1991; 83:1734-9. https://pubmed.ncbi.nlm.nih.gov/1770552

136. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991; 302:1302-5. https://pubmed.ncbi.nlm.nih.gov/2059685

137. Forman D. Helicobacter pylori infection: a novel risk factor in the etiology of gastric cancer. J Natl Cancer Inst. 1991; 83:1702-3. https://pubmed.ncbi.nlm.nih.gov/1770545

138. Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am. 1993; 22:89-104. https://pubmed.ncbi.nlm.nih.gov/8449573

139. Correa P. Is gastric carcinoma an infectious disease? N Engl J Med. 1991; 325:1170-1.

140. Isaacson PG, Spencer J. Is gastric lymphoma an infectious disease? Hum Pathol. 1993; 24:569-70.

141. Reviewers’ comments (personal observations) on Helicobacter pylori 1995 revisions.

142. Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994; 89(Suppl):S116-28.

143. NIH Consensus Development Panel on. Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994; 272:65-9. https://pubmed.ncbi.nlm.nih.gov/8007082

144. Labenz J, Gyenes E, Rühl GH et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut. 1993; 34:1167-70. https://pubmed.ncbi.nlm.nih.gov/8406147

145. Anon. Drugs for treatment of peptic ulcers. Med Lett Drugs Ther. 1994; 36:65-7. https://pubmed.ncbi.nlm.nih.gov/7912812

146. Markham A, McTavish D. Clarithromycin and omeprazole: as Helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs. 1996; 51:161-78. https://pubmed.ncbi.nlm.nih.gov/8741237

147. Soll AH. Medical treatment of peptic ulcer disease. JAMA. 1996; 275:622-9. https://pubmed.ncbi.nlm.nih.gov/8594244

148. Labenz J, Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol. 1994; 89:1785-8. https://pubmed.ncbi.nlm.nih.gov/7942667

149. Wang WM, Chen CY, Jan CM et al. Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol. 1994; 89:1793-6. https://pubmed.ncbi.nlm.nih.gov/7942669

150. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995; 333:984-91. https://pubmed.ncbi.nlm.nih.gov/7666920

151. Hackelsberger A, Malfertheiner P. A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection. Drug Saf. 1996; 15:30-52. https://pubmed.ncbi.nlm.nih.gov/8862962

152. Rauws EAJ, van der Hulst RWM. Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Drugs. 1995; 6:984-90.

153. van der Hulst RWM, Keller JJ, Rauws EAJ et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996; 1:6-19. https://pubmed.ncbi.nlm.nih.gov/9398908

154. Lind T, Veldhuyzen van Zanten S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter. 1996; 1:138-44. https://pubmed.ncbi.nlm.nih.gov/9398894

155. Anon. The choice of antibacterial drugs. Med Lett Drugs Ther. 1996; 38:25-34. https://pubmed.ncbi.nlm.nih.gov/8598824

156. Murray DM, DuPont HL. Reply. (Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated.) Clin Infect Dis. 1993; 17:294-5.

157. George LL, Borody TJ, Andrews P et al. Cure of duodenal ulcer after eradication of H. pylori . Med J Aust. 1990; 153:145-9. https://pubmed.ncbi.nlm.nih.gov/1974027

158. Fennerty MB. Practice guidelines for treatment of peptic ulcer disease. JAMA. 1996; 276:1135. https://pubmed.ncbi.nlm.nih.gov/8827957

159. Soll AH. Practice guidelines for treatment of peptic ulcer disease. JAMA. 1996; 276:1136-7.

160. Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997; 54:473-500. https://pubmed.ncbi.nlm.nih.gov/9279507

161. TAP Pharmaceuticals, Inc. Prevacid (lansoprazole) delayed-release capsules prescribing information. Deerfield, IL; 1997 Aug.

162. Garnett RG. Lansoprazole: a proton pump inhibitor. Ann Pharmacother. 1996; 30:1425. https://pubmed.ncbi.nlm.nih.gov/8968456

163. Zimmerman AE, Katona BG. Lansoprazole: a comprehensive review. Pharmacotherapy. 1997; 17:308-26. https://pubmed.ncbi.nlm.nih.gov/9085323

164. Hatlebakk JG, Nesje LB, Hausken T et al. Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Scand J Gastroenterol. 1995; 11:1053-7.

165. DeVault KR, Castell DO, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999; 94:1434-42. https://pubmed.ncbi.nlm.nih.gov/10364004

166. Richter JE. Treatment of severe reflux esophagitis. Ann Intern Med. 1986; 104:588-9. Letter.

167. Lieberman DA, Keeffe EB. Treatment of severe esophagitis with cimetidine and metoclopramide. Ann Intern Med. 1986; 104:21-6. https://pubmed.ncbi.nlm.nih.gov/3940501

168. Castell DO. Medical therapy for reflux esophagitis: 1986 and beyond. Ann Intern Med. 1986; 104:112-4. https://pubmed.ncbi.nlm.nih.gov/2866742

169. Richter JE, A critical review of current medical therapy for gastroesophageal reflux disease. J Clin Gastroenterol. 1986; 8(Suppl 1):72-80.

170. Ganzani L, Casey DE, Hofman WF et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993; 153:1469-75. https://pubmed.ncbi.nlm.nih.gov/8512437

171. Behar J, Brand DL, Brown FC et al. Cimetidine in the treatment of symptomatic gastroesophageal reflux. Gastroenterology. 1978; 74:441-8. https://pubmed.ncbi.nlm.nih.gov/340333

172. Sontag S, Robinson M, McCallum RW et al. Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial. Arch Intern Med. 1987; 1485-91.

173. Euler AR, Murdock RH, Wilson TH et al. Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol. 1993; 88:520-4. https://pubmed.ncbi.nlm.nih.gov/8470632

174. Antonson CW, Robinson MG, Hawkins TM et al. High doses of histamine antagonists do not prevent relapses of peptic esophagitis following therapy with a proton pump inhibitor. Gastroenterology. 1990; 98:A16.

175. Laheij RJF, Sturkenboom MCJM, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955-60.

a. Reliant. Axid (nizatidine) capsules prescribing information. Liberty Corner, NJ; 2001 Mar 19.

b. Whitehall-Robins Healthcare. Axid AR product information approved Apr 1, 1998. From FDA Website. 2004 Mar 9. http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20555-S3_AxidAr_prntlbl.pdf

c. AHFS drug information 2005. McEvoy GK, ed. Nizatidine. Bethesda, MD: American Society of Health-System Pharmacists. 2005: 2824-9.

Medical Disclaimer